Relapsed or Refractory Lymphoma (DBCOND0152115)

Identifiers

Synonyms

Relapsed and/or Refractory Lymphoma / Relapsed or Refractory Lymphomas

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Lenalidomide	A thalidomide derivative used to treat multiple myeloma and anemia in low to intermediate risk myelodysplastic syndrome.	Prostaglandin G/H synthase 2target Tumor necrosis factor ligand superfamily member 11target Cadherin-5target Protein cereblontarget ATP-dependent translocase ABCB1transporter Tumor necrosis factortarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT01742988	Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma	Fimepinostat Rituximab Venetoclax	treatment	1	completed
NCT06132503	Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors	LP-284	treatment	1	recruiting
NCT04458389	A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas	No drug interventions	treatment	1 / 2	recruiting
NCT05571787	HMPL-523 Food Effect and Proton Pump Inhibitor Study	Rabeprazole	other	1	completed
NCT05602597	HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI	Fluconazole Itraconazole Rabeprazole Rifampin	other	1	completed
NCT05720767	HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study	Itraconazole Rifampin	other	1	completed